MaaT Pharma Shifts MaaT034 To FDA Path After Xervyteg EU Rejection

MaaT Pharma's dual regulatory setback and pivot carries direct implications for CMC and regulatory affairs teams navigating multi-jurisdictional development strategies: the CHMP has maintained its negative opinion on the Conditional Marketing Authorization Application for MaaT013 (Xervyteg®) following re-examination, closing the European conditional approval pathway and forcing a full reorientation toward a randomized Phase 3 program.

The proposed registrational trial, named PHOENIX, is designed to support future submissions in the U.S., Europe, and selected other territories, with protocol finalization informed by feedback from a Type C interaction with the FDA. That interaction provides a regulatory framework for U.S. development activities, a meaningful signal for regulatory affairs leads assessing how FDA engagement can be leveraged after a negative EMA outcome.

For MaaT034, the company has scheduled a CMC-focused pre-IND meeting with the FDA for October 2026. The explicit CMC framing of that meeting is notable: it signals that manufacturing controls, process characterization, and analytical method development are the near-term gating items for U.S. IND submission, not clinical design. QA directors and CMC leads at comparable microbiome or biologics programs should read this as a reminder that regulatory agencies are scrutinizing manufacturing readiness early in the development sequence.

Financially, the picture is constrained. Revenue fell to €1.1 million in H1 2026 from €2.4 million in H1 2025, largely reflecting the transition of the European Early Access Program to Clinigen under a licensing agreement effective January 1, 2026. Patient demand within the EAP remained globally stable, but the revenue structure has shifted. Cash and cash equivalents stood at €17.1 million as of June 30, 2026, with the runway now estimated to reach only December 2026 under the current operating plan.

The company is actively exploring financing and strategic partnership opportunities. More than 550 Early Access Program authorizations have been issued across 14 countries since 2019, and the CHRONOS real-world dataset, published in Bone Marrow Transplantation in April 2026, reported 29% 12-month overall survival and 37% Day-28 GI-ORR in third-line steroid-refractory GI-aGvHD patients treated outside microbiome-based therapies, providing comparative context for the PHOENIX trial design.

The October 2026 pre-IND meeting with FDA on MaaT034 CMC activities will serve as an early indicator of whether the company's manufacturing readiness can support a credible IND filing timeline within its current cash position.

Source: MaaT Pharma via corporate press release, September 29, 2026.